NHS England chief executive Simon Stevens has indicated that chimeric antigen receptor T-cell therapy (CAR-T) could be available on the NHS this year, offering eligible patients a ‘ground-breaking’ approach to treating cancer.
Read More
Novartis has submitted an application to the European Medicines Agency for its CAR-T therapy CTL019 for two haematological indications.
Read More
Novartis’ CTL019 has taken a giant leap towards the finishing line in the race to get the first cancer killing CAR-T cell therapy on the market having won the support of an FDA advisory panel.
Read More
Oxford BioMedica has sealed a major deal with Novartis to supply the Swiss drug giant with lentiviral vectors used to create cell therapy products, including CTL019 and other undisclosed Chimeric Antigen Receptor T cell (CART) products.
Read More
Novartis’ closely-watched CTL019 has elicited a strong response in cancer patients taking the experimental CAR-T cell therapy in a mid-stage trial.
Read More
Novartis has stepped ahead in the race to get the first cancer-killing CAR-T cell therapy on the market having successfully filed a biologics license application with US regulators.
Read More
